Spyre Therapeutics, Inc.
About Spyre Therapeutics, Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$155.2M
- Total assets
- $777.8M
- Market cap
- $6.4B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $209.6M
- Operating income
- -$209.6M
- Income tax
- -$15.0K
- Net income
- -$155.2M
Balance sheet
- Total assets
- $777.8M
- Current assets
- $777.8M
- Total liabilities
- $62.5M
- Current liabilities
- $58.7M
- Shareholders’ equity
- $715.2M
Cash flow
- Operating cash flow
- -$169.3M
- Investing cash flow
- -$143.5M
- Financing cash flow
- $309.0M
- Net cash flow
- -$3.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $6.4B
- Shares outstanding
- 88.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 7, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $155.2M in FY2025.
- Trading 8% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Spyre Therapeutics, Inc..
Write a review
News about Spyre Therapeutics, Inc.
News & sentiment via Polygon.io
